📊 VERA Key Takeaways
Is Vera Therapeutics, Inc. (VERA) a Good Investment?
Vera Therapeutics is a pre-commercial stage biotech company with zero revenue and operating losses of $125.1M annually, burning cash at approximately $106.5M with roughly 1 year of runway remaining. Despite a fortress balance sheet ($499.7M equity, 0.15x debt/equity, 13.64x liquidity), the absence of commercialized products, accelerating net losses (-69.5% YoY), and lack of visibility to profitability create substantial fundamental risk without supporting clinical or regulatory milestone data.
Vera Therapeutics, Inc. Key Strengths (VERA)
- Strong balance sheet with $499.7M stockholders equity and only $122.0M total liabilities
- Exceptional liquidity position with 13.64x current ratio and $114.4M cash reserves
- Conservative capital structure with 0.15x debt/equity and only $75.0M long-term debt
VERA Stock Risks: Vera Therapeutics, Inc. Investment Risks
- Zero revenue indicates pre-commercial stage with no proven market viability or commercialization timeline
- Annual operating cash burn of $106.5M provides approximately 12 months of runway at current levels, necessitating capital raise or major milestone achievement
- Deteriorating profitability with net losses of $121.0M, negative ROE of -24.2%, and declining diluted EPS (-69.5% YoY)
- No visibility to profitability timeline with negative interest coverage (-32.8x) and no identifiable revenue-generating operations
Key Metrics to Watch
- Quarterly operating cash burn rate and months of cash runway remaining
- Clinical trial progression, regulatory filings, and time to potential commercialization
- Achievement of clinical or regulatory milestones that reduce commercial risk
- Capital raise needs and resulting equity dilution impact on shareholders
Vera Therapeutics, Inc. (VERA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.64x current ratio provides a solid financial cushion.
VERA Profit Margin, ROE & Profitability Analysis
VERA vs Healthcare Sector: How Vera Therapeutics, Inc. Compares
How Vera Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vera Therapeutics, Inc. Stock Overvalued? VERA Valuation Analysis 2026
Based on fundamental analysis, Vera Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vera Therapeutics, Inc. Balance Sheet: VERA Debt, Cash & Liquidity
VERA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vera Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.25 indicates the company is currently unprofitable.
VERA Revenue Growth, EPS Growth & YoY Performance
Vera Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
VERA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vera Therapeutics, Inc. (CIK: 0001831828)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VERA
What is the AI rating for VERA?
Vera Therapeutics, Inc. (VERA) has an AI grade of D with 35% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VERA's key strengths?
Claude: Strong balance sheet with $499.7M stockholders equity and only $122.0M total liabilities. Exceptional liquidity position with 13.64x current ratio and $114.4M cash reserves.
What are the risks of investing in VERA?
Claude: Zero revenue indicates pre-commercial stage with no proven market viability or commercialization timeline. Annual operating cash burn of $106.5M provides approximately 12 months of runway at current levels, necessitating capital raise or major milestone achievement.
What is VERA's revenue and growth?
Vera Therapeutics, Inc. reported revenue of N/A.
Does VERA pay dividends?
Vera Therapeutics, Inc. does not currently pay dividends.
Where can I find VERA SEC filings?
Official SEC filings for Vera Therapeutics, Inc. (CIK: 0001831828) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VERA's EPS?
Vera Therapeutics, Inc. has a diluted EPS of $-1.69.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VERA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Vera Therapeutics, Inc. has a D grade with 35% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VERA stock overvalued or undervalued?
Valuation metrics for VERA: ROE of -24.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VERA's AI grade for 2026?
Our dual AI analysis gives Vera Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VERA's free cash flow?
Vera Therapeutics, Inc.'s operating cash flow is $-106.5M, with capital expenditures of $23.0K.
How does VERA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -24.2% (avg: 15%), current ratio 13.64 (avg: 2).